David A. Siegel Codiak Bio Sciences, Inc. Transaction History

Two Sigma Advisers, LP

  • $43.8 Billion
  • Q2 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023
BUY
$0.32 - $0.9 $4,352 - $12,240
13,600 New
13,600 $5,000

Others Institutions Holding CDAK

# of Institutions
1
Shares Held
238K
Call Options Held
0
Put Options Held
0
View Full List

About Codiak BioSciences, Inc.

CDAK Quotes by TradingView
  • Ticker CDAK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,995,200
  • Market Cap $360K
  • Description
  • Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of...
More about CDAK
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email